01699nam a2200193Ia 4500003000400000005001700004008004100021050003100062100002300093245009700116264004700213300002900260500002000289505082200309942003101131999001701162952015701179952016901336OSt20260718102240.0230508s2022 xx 000 0 und d aAllied HD 9666.4bL36 20221 aLaMattina, John L.10aPharma and profits : bbalancing innovation, medicine, and drug prices /cJohn L. LaMattina. aHoboken, NJ : bJohn Wiley & Sons, c2022. axii, 100 pages ;c23 cm. aIncludes index.0 ach. 1. The $1000 pill: the fiscal consequences of curing hepatitis C — ch. 2. Enter the players: FDA approval does not guarantee commercial success — ch. 3. Pandemic: mRNA vaccine and the race for a cure — ch. 4. Federal investment in r&d: why the government does not deserve a piece of biopharma’s profits? — ch. 5. Inaulin: the true cost of a 100-year-old drug — ch. 6. The costly alzheimer’s disease drug: a questionable breakthrough — ch. 7. Gene therapy: how much a life worth? — ch. 8. Proving the value of expensive drug: should we pay for drugs whose ultimate value is unknown? — cn. 9. Generic drugs: built-in cost controls — ch. 10. About those soaring pharma profits: are they driving healthcare costs? — ch. 11. Schemes to lower drug prices: the impact of reduced resources on r&d. 2lcccBKkEAC Cavite-Allied c33453d33453 00102lcc4070aCAVITEbCAVITEcEAC Cavite-Alliedd2023-05-16g2695.50l0oAllied HD 9666.4 L36 2022pML16622r2026-05-29 00:00:00tc.1w2023-05-16yBK 00102lcc4070aCAVITEbCAVITEcEAC Cavite-Alliedd2023-11-20g2695.50l0oAllied HD 9666.4 L36 2022 c.2pML17504r2026-05-29 00:00:00tc2v2695.50w2024-01-05yBK